Metformin vs NAD+
A side-by-side research comparison of Metformin and NAD+ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Metformin | NAD+ |
|---|---|---|
| Full name | Metformin Hydrochloride | Nicotinamide Adenine Dinucleotide (NAD+ / NMN / NR) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved (off-label for longevity) | Research compound |
| Mechanism | Activates AMP-activated protein kinase (AMPK), inhibits mitochondrial complex I, reduces hepatic glucose output, and activates autophagy. Mimics the metabolic benefits of caloric restriction. | NAD+ serves as cofactor for sirtuins (SIRT1-7), PARPs (DNA repair), and CD38. Declining NAD+ impairs mitochondrial function and epigenetic maintenance. Restoration reactivates longevity pathways. |
| Molecular weight | 165.62 Da | 663.4 Da |
| Half-life | ~6.2 hours | 1-4 hours (IV), 4-8h (oral precursors) |
| Bioavailability | ~50-60% oral | 100% (IV), variable (oral 5-30%) |
| Typical dose | 500-1000 mg | 250-500mg IV or 500-1000mg NMN oral |
| Frequency | 1-2x daily | Weekly (IV) or Daily (oral) |
| Route | Oral tablet (extended-release preferred) | IV infusion or Oral (precursors) |
Metformin reported benefits
- AMPK activation
- Anti-aging cellular effects
- Cancer risk reduction
- Cardiovascular protection
- Blood sugar regulation
- Longevity support
NAD+ reported benefits
- Restored cellular energy
- Enhanced DNA repair
- Sirtuin activation
- Improved mitochondrial function
- Cognitive clarity
- Anti-aging
Related comparisons
Research and educational reference only. Not medical advice.